MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 532375 | Name: NVP-2
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

NVP-2 is a strong, remarkably selective CDK9 inhibitor with an equally potent CDK10/CycM inhibitor. NVP-2 represents a highly promising starting point to design analogs that will hopefully inhibit selectively CDK10/CycM. inhibits CDK9/CycT activity with an IC50 of 0.514 nM. NVP-2 displays inhibitory effcts on CDK1/CycB, CDK2/CycA and CDK16/CycY kinases.

Chemical Structure

NVP-2
NVP-2
CAS#1263373-43-8

Theoretical Analysis

MedKoo Cat#: 532375

Name: NVP-2

CAS#: 1263373-43-8

Chemical Formula: C27H37ClN6O2

Exact Mass: 512.2667

Molecular Weight: 513.08

Elemental Analysis: C, 63.21; H, 7.27; Cl, 6.91; N, 16.38; O, 6.24

Price and Availability

Size Price Availability Quantity
25mg USD 340.00 2 Weeks
50mg USD 530.00 2 Weeks
100mg USD 850.00 2 Weeks
200mg USD 1,350.00 2 Weeks
500mg USD 2,350.00 2 Weeks
1g USD 3,750.00 2 Weeks
2g USD 5,950.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
NVP-2; NVP 2; NVP2.
IUPAC/Chemical Name
4-({[6-(5-chloro-2-{[(1r,4r)-4-{[(2R)-1-methoxypropan-2-yl]amino}cyclohexyl]amino}pyridin-4-yl)pyridin-2-yl]amino}methyl)oxane-4-carbonitrile
InChi Key
XWQVQSXLXAXOPJ-NJDAHSKKSA-N
InChi Code
InChI=1S/C27H37ClN6O2/c1-19(16-35-2)32-20-6-8-21(9-7-20)33-26-14-22(23(28)15-30-26)24-4-3-5-25(34-24)31-18-27(17-29)10-12-36-13-11-27/h3-5,14-15,19-21,32H,6-13,16,18H2,1-2H3,(H,30,33)(H,31,34)/t19-,20-,21-/m1/s1
SMILES Code
N#CC1(CNC2=NC(C3=CC(N[C@H]4CC[C@H](N[C@H](C)COC)CC4)=NC=C3Cl)=CC=C2)CCOCC1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Cyclin-dependent kinases (CDKs) constitute a family of 20 serine/threonine protein kinases that play pivotal roles in the regulation of numerous important molecular and cellular processes. CDKs have long been considered promising therapeutic targets in a variety of pathologies, and the recent therapeutic success of CDK4/6 inhibitors in breast cancers has renewed interest in their therapeutic potential. Small-molecule inhibitors have been identified for every human CDK, except for CDK10
Product Data
Product Data
Instruction
View handling instruction
Biological target:
NVP-2 is a ATP-competitive cyclin dependent kinase 9 (CDK9) probe, inhibits CDK9/CycT activity with an IC50 of 0.514 nM.
In vitro activity:
This study reports the identification of an optimized peptide phosphorylation substrate of CDK10/CycM and the development of the first homogeneous, miniaturized CDK10/CycM in vitro kinase assay. This study reveals the ability of known CDK inhibitors, among which clinically tested SNS-032, riviciclib, flavopiridol, dinaciclib, AZD4573 and AT7519, to potently inhibit CDK10/CycM. This study also shows that NVP-2, a strong, remarkably selective CDK9 inhibitor is an equally potent CDK10/CycM inhibitor. Reference: Front Chem. 2020 Feb 27;8:147. https://pubmed.ncbi.nlm.nih.gov/32175313/
In vivo activity:
NVP administration caused a dose-dependent, significant (p < 0.05) elevation of lipid peroxidation measured as malondialdehyde (MDA) content in the liver, kidney and testis of the rats. Hepatic, renal and testicular MDA were increased by 107%, 80% and 163%, respectively, in NVP2-treated rats. Elevation in MDA was accompanied by a significant (p < 0.05) decrease in the activities of hepatic, renal and testicular superoxide dismutase and catalase. NVP2 caused 43% and 32% decrease in spermatozoa motility and live/dead sperm count, respectively, and 94% increase in total sperm abnormalities. Reference: Hum Exp Toxicol. 2012 Jul;31(7):676-85. https://pubmed.ncbi.nlm.nih.gov/22027508/
Solvent mg/mL mM
Solubility
DMSO 83.8 163.27
Ethanol 75.7 147.45
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 513.08 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Guhan SM, Shaughnessy M, Rajadurai A, Taylor M, Kumar R, Ji Z, Rashid S, Flaherty K, Tsao H. The Molecular Context of Vulnerability for CDK9 Suppression in Triple Wild-Type Melanoma. J Invest Dermatol. 2021 Aug;141(8):2018-2027.e4. doi: 10.1016/j.jid.2020.12.035. Epub 2021 Mar 18. PMID: 33745909; PMCID: PMC8316294. 2. Robert T, Johnson JL, Guichaoua R, Yaron TM, Bach S, Cantley LC, Colas P. Development of a CDK10/CycM in vitro Kinase Screening Assay and Identification of First Small-Molecule Inhibitors. Front Chem. 2020 Feb 27;8:147. doi: 10.3389/fchem.2020.00147. PMID: 32175313; PMCID: PMC7056863. 3. Adaramoye OA, Adesanoye OA, Adewumi OM, Akanni O. Studies on the toxicological effect of nevirapine, an antiretroviral drug, on the liver, kidney and testis of male Wistar rats. Hum Exp Toxicol. 2012 Jul;31(7):676-85. doi: 10.1177/0960327111424304. Epub 2011 Oct 25. PMID: 22027508.
In vitro protocol:
1. Guhan SM, Shaughnessy M, Rajadurai A, Taylor M, Kumar R, Ji Z, Rashid S, Flaherty K, Tsao H. The Molecular Context of Vulnerability for CDK9 Suppression in Triple Wild-Type Melanoma. J Invest Dermatol. 2021 Aug;141(8):2018-2027.e4. doi: 10.1016/j.jid.2020.12.035. Epub 2021 Mar 18. PMID: 33745909; PMCID: PMC8316294. 2. Robert T, Johnson JL, Guichaoua R, Yaron TM, Bach S, Cantley LC, Colas P. Development of a CDK10/CycM in vitro Kinase Screening Assay and Identification of First Small-Molecule Inhibitors. Front Chem. 2020 Feb 27;8:147. doi: 10.3389/fchem.2020.00147. PMID: 32175313; PMCID: PMC7056863.
In vivo protocol:
1. Adaramoye OA, Adesanoye OA, Adewumi OM, Akanni O. Studies on the toxicological effect of nevirapine, an antiretroviral drug, on the liver, kidney and testis of male Wistar rats. Hum Exp Toxicol. 2012 Jul;31(7):676-85. doi: 10.1177/0960327111424304. Epub 2011 Oct 25. PMID: 22027508.
This message contains search results from the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM). Do not reply directly to this message Sent On: Thu Oct 22 13:27:15 2020 Search: NVP-2 20 selected items PubMed Results Items 1-20 of 20 (Display the 20 citations in PubMed) 1: Robert T, Johnson JL, Guichaoua R, Yaron TM, Bach S, Cantley LC, Colas P. Development of a CDK10/CycM in vitro Kinase Screening Assay and Identification of First Small-Molecule Inhibitors. Front Chem. 2020 Feb 27;8:147. doi: 10.3389/fchem.2020.00147. PMID: 32175313; PMCID: PMC7056863. 2: Dutta B, Dey A, Maity S, Sinha C, Ray PP, Mir MH. Supramolecular Assembly of a Zn(II)-Based 1D Coordination Polymer through Hydrogen Bonding and π···π Interactions: Crystal Structure and Device Applications. ACS Omega. 2018 Sep 27;3(9):12060-12067. doi: 10.1021/acsomega.8b01924. PMID: 31459286; PMCID: PMC6645665. 3: Sathish V, Krishnan MM, Velayudham M, Thanasekaran P, Lu KL, Rajagopal S. Host-guest interaction studies of polycyclic aromatic hydrocarbons (PAHs) in alkoxy bridged binuclear rhenium (I) complexes. Spectrochim Acta A Mol Biomol Spectrosc. 2019 Nov 5;222:117160. doi: 10.1016/j.saa.2019.117160. Epub 2019 May 28. PMID: 31176159. 4: Dutta B, Dey A, Sinha C, Ray PP, Mir MH. Sunlight-Induced Topochemical Photodimerization and Switching of the Conductivity of a Metal-Organic Compound. Inorg Chem. 2019 May 6;58(9):5419-5422. doi: 10.1021/acs.inorgchem.9b00619. Epub 2019 Apr 12. PMID: 30978011. 5: Wright P, Kelsall J, Healing G, Sanderson J. Differential expression of cyclin-dependent kinases in the adult human retina in relation to CDK inhibitor retinotoxicity. Arch Toxicol. 2019 Mar;93(3):659-671. doi: 10.1007/s00204-018-2376-8. Epub 2019 Jan 8. PMID: 30617560. 6: Gravely S, Thrasher JF, Cummings KM, Ouimet J, McNeill A, Meng G, Lindblom EN, Loewen R, O'Connor RJ, Thompson ME, Hitchman SC, Hammond D, Heckman BW, Borland R, Yong HH, Elton-Marshall T, Bansal-Travers M, Gartner C, Fong GT. Discussions between health professionals and smokers about nicotine vaping products: results from the 2016 ITC Four Country Smoking and Vaping Survey. Addiction. 2019 Oct;114 Suppl 1(Suppl 1):71-85. doi: 10.1111/add.14527. Epub 2019 Mar 7. PMID: 30548374; PMCID: PMC6559875. 7: Dutta B, Dey A, Sinha C, Ray PP, Mir MH. Photochemical Structural Transformation of a Linear 1D Coordination Polymer Impacts the Electrical Conductivity. Inorg Chem. 2018 Jul 16;57(14):8029-8032. doi: 10.1021/acs.inorgchem.8b00833. Epub 2018 Jun 28. PMID: 29952564. 8: Olson CM, Jiang B, Erb MA, Liang Y, Doctor ZM, Zhang Z, Zhang T, Kwiatkowski N, Boukhali M, Green JL, Haas W, Nomanbhoy T, Fischer ES, Young RA, Bradner JE, Winter GE, Gray NS. Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nat Chem Biol. 2018 Feb;14(2):163-170. doi: 10.1038/nchembio.2538. Epub 2017 Dec 18. PMID: 29251720; PMCID: PMC5912898. 9: Embling LA, Zagami D, Sriram KB, Gordon RJ, Sivakumaran P. Effect of changing from the National Health and Nutritional Examination Survey III spirometry reference range to that of the Global Lung Initiative 2012 at Gold Coast Hospital and Health Service. J Thorac Dis. 2016 Dec;8(12):3739-3743. doi: 10.21037/jtd.2016.12.13. PMID: 28149572; PMCID: PMC5227233. 10: Mbuagbaw L, Mursleen S, Irlam JH, Spaulding AB, Rutherford GW, Siegfried N. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Cochrane Database Syst Rev. 2016 Dec 10;12(12):CD004246. doi: 10.1002/14651858.CD004246.pub4. PMID: 27943261; PMCID: PMC5450880. 11: Bustos M, Venkataramanan R, Caritis S. Nausea and vomiting of pregnancy - What's new? Auton Neurosci. 2017 Jan;202:62-72. doi: 10.1016/j.autneu.2016.05.002. Epub 2016 May 13. PMID: 27209471; PMCID: PMC5107351. 12: Srivastava A, Mandal P, Kumar R. Solid state thermal degradation behaviour of graft copolymers of carboxymethyl cellulose with vinyl monomers. Int J Biol Macromol. 2016 Jun;87:357-65. doi: 10.1016/j.ijbiomac.2016.03.004. Epub 2016 Mar 6. PMID: 26959171. 13: Palacios R, Pérez-Hernández IA, Martínez MA, Mayorga ML, González-Domenech CM, Omar M, Olalla J, Romero A, Romero JM, Pérez-Camacho I, Hernández-Quero J, Santos J. Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART. Eur J Clin Microbiol Infect Dis. 2016 May;35(5):815-9. doi: 10.1007/s10096-016-2602-3. Epub 2016 Feb 15. PMID: 26879392. 14: Podzamczer D, Rojas JF, Neves I, Ferrer E, Llibre JM, Leal M, Gorgolas M, Jose CM, Gatell JM, Abreu RC, Curto J, Domingo P, Pilar BM, Rozas N. Effectiveness and tolerability of abacavir-lamivudine-nevirapine (ABC/3TC/NVP) in a multicentre cohort of HIV-infected, ARV-naïve patients. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19773. doi: 10.7448/IAS.17.4.19773. PMID: 25397517; PMCID: PMC4225404. 15: Sathish V, Ramdass A, Lu ZZ, Velayudham M, Thanasekaran P, Lu KL, Rajagopal S. Aggregation-induced emission enhancement in alkoxy-bridged binuclear rhenium(I) complexes: application as sensor for explosives and interaction with microheterogeneous media. J Phys Chem B. 2013 Nov 21;117(46):14358-66. doi: 10.1021/jp407939j. Epub 2013 Nov 7. PMID: 24175920. 16: Ivan E, Crowther NJ, Mutimura E, Osuwat LO, Janssen S, Grobusch MP. Helminthic infections rates and malaria in HIV-infected pregnant women on anti- retroviral therapy in Rwanda. PLoS Negl Trop Dis. 2013 Aug 15;7(8):e2380. doi: 10.1371/journal.pntd.0002380. PMID: 23967365; PMCID: PMC3744439. 17: Taneja C, Juday T, Gertzog L, Edelsberg J, Correll T, Hebden T, Oster G. Adherence and persistence with non-nucleoside reverse transcriptase inhibitor- based antiretroviral regimens. Expert Opin Pharmacother. 2012 Oct;13(15):2111-8. doi: 10.1517/14656566.2012.719875. Epub 2012 Sep 13. PMID: 22970926. 18: Wang C, Javadi A, Ghaffari M, Gong S. A pH-sensitive molecularly imprinted nanospheres/hydrogel composite as a coating for implantable biosensors. Biomaterials. 2010 Jun;31(18):4944-51. doi: 10.1016/j.biomaterials.2010.02.073. Epub 2010 Mar 25. PMID: 20346500. 19: Mitha MK, Jayabalan M. Studies on biodegradable and crosslinkable poly(castor oil fumarate)/poly(propylene fumarate) composite adhesive as a potential injectable biomaterial. J Mater Sci Mater Med. 2009 Dec;20 Suppl 1:S203-11. doi: 10.1007/s10856-008-3518-y. Epub 2008 Jul 1. PMID: 18592346. 20: Liu L, Lu HZ, Henry M, Tamalet C. Polymorphism and drug selected mutations of reverse transcriptase gene in 102 HIV-1 infected patients living in China. J Med Virol. 2007 Oct;79(10):1593-9. doi: 10.1002/jmv.20998. PMID: 17705165.

View History

IWP2G9

IWP2G9